Novartis: FDA grants priority review to lung cancer drug
(CercleFinance.com) - Novartis said that US health regulators have granted a priority review to its experimental drug capmatinib for the treatment of a specific form of advanced non-small cell lung cancer, accelerating the drug's review process.
The Food and Drug Administration (FDA) has granted priority review to capmatinib's new drug application as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer.
If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis.
The review is expected to be completed within six months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.